Literature DB >> 6565706

Disk diffusion antimicrobial susceptibility testing of members of the family Legionellaceae including erythromycin-resistant variants of Legionella micdadei.

J N Dowling, D A McDevitt, A W Pasculle.   

Abstract

Disk diffusion antimicrobial susceptibility testing of members of the family Legionellaceae was accomplished on buffered charcoal yeast extract agar by allowing the bacteria to grow for 6 h before placement of the disks, followed by an additional 42-h incubation period before the inhibitory zones were measured. This system was standardized by comparing the zone sizes with the MICs for 20 antimicrobial agents of nine bacterial strains in five Legionella species and of 19 laboratory-derived, erythromycin-resistant variants of Legionella micdadei. A high, linear correlation between zone size and MIC was found for erythromycin, trimethoprim, penicillin, ampicillin, carbenicillin, cephalothin, cefamandole, cefoxitin, moxalactam, chloramphenicol, vancomycin, and clindamycin. Disk susceptibility testing could be employed to screen Legionella isolates for resistance to any of these antimicrobial agents, of which only erythromycin is known to be efficacious in the treatment of legionellosis. With selected antibiotics, disk susceptibility patterns also appeared to accurately identify to the species level the legionellae. The range of the MICs of the legionellae for rifampin and the aminoglycosides was too small to determine whether the correlation of zone size with MIC was linear. However, laboratory-derived, high-level rifampin-resistant variants of L. micdadei demonstrated no inhibition zone around the rifampin disk, indicating that disk susceptibility testing would likely identify a rifampin-resistant clinical isolate. Of the antimicrobial agents tested, the only agents for which disk susceptibility testing was definitely not possible on buffered charcoal yeast extract agar were oxacillin, the tetracyclines, and the sulfonamides.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6565706      PMCID: PMC271172          DOI: 10.1128/jcm.19.6.723-729.1984

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  In vivo susceptibility of the Legionnaires disease bacterium to ten antimicrobial agents.

Authors:  V J Lewis; W L Thacker; C C Shepard; J E McDade
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

2.  Opportunistic lung infection due to "Pittsburgh Pneumonia Agent".

Authors:  R L Myerowitz; A W Pasculle; J N Dowling; G J Pazin; M Puerzer; R B Yee; C R Rinaldo; T R Hakala
Journal:  N Engl J Med       Date:  1979-11-01       Impact factor: 91.245

3.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

4.  The rickettsia-like organisms TATLOCK (1943) and HEBA (1959): bacteria phenotypically similar to but genetically distinct from Legionella pneumophila and the WIGA bacterium.

Authors:  G A Hébert; C W Moss; L K McDougal; F M Bozeman; R M McKinney; D J Brenner
Journal:  Ann Intern Med       Date:  1980-01       Impact factor: 25.391

5.  Inactivation of beta-lactam antibiotics by Legionella pneumophila.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

6.  In vitro activity of antimicrobial agents on Legionnaires disease bacterium.

Authors:  C Thornsberry; C N Baker; L A Kirven
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

7.  Liquid medium for growth of Legionella pneumophila.

Authors:  J D Ristroph; K W Hedlund; R G Allen
Journal:  J Clin Microbiol       Date:  1980-01       Impact factor: 5.948

8.  Legionnaires' disease: description of an epidemic of pneumonia.

Authors:  D W Fraser; T R Tsai; W Orenstein; W E Parkin; H J Beecham; R G Sharrar; J Harris; G F Mallison; S M Martin; J E McDade; C C Shepard; P S Brachman
Journal:  N Engl J Med       Date:  1977-12-01       Impact factor: 91.245

9.  Pittsburgh pneumonia agent: direct isolation from human lung tissue.

Authors:  A W Pasculle; J C Feeley; R J Gibson; L G Cordes; R L Myerowitz; C M Patton; G W Gorman; C L Carmack; J W Ezzell; J N Dowling
Journal:  J Infect Dis       Date:  1980-06       Impact factor: 5.226

10.  Antibiotic treatment of guinea-pigs infected with agent of Legionnaires' disease.

Authors:  D W Fraser; I Wachsmuth; C Bopp; J C Feeley; T F Tsai
Journal:  Lancet       Date:  1978-01-28       Impact factor: 79.321

View more
  7 in total

1.  The Legionella pneumophila tatB gene facilitates secretion of phospholipase C, growth under iron-limiting conditions, and intracellular infection.

Authors:  Ombeline Rossier; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

2.  Sequencing of the rpoB gene in Legionella pneumophila and characterization of mutations associated with rifampin resistance in the Legionellaceae.

Authors:  K Nielsen; P Hindersson; N Hoiby; J M Bangsborg
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Laboratory- and species-specific interpretive breakpoints for disk diffusion tests of chloramphenicol susceptibility of Haemophilus influenzae.

Authors:  G Kronvall; S Ringertz; I Karlsson; E Göransson; K Dornbusch
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

Review 4.  Legionnaires disease: historical perspective.

Authors:  W C Winn
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

5.  Rifampin resistance of Legionella pneumophila is not increased during therapy for experimental Legionnaires disease: study of rifampin resistance using a guinea pig model of Legionnaires disease.

Authors:  P H Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

6.  Isolation and preliminary characterization of erythromycin-resistant variants of Legionella micdadei and Legionella pneumophila.

Authors:  J N Dowling; D A McDevitt; A W Pasculle
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

7.  Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents.

Authors:  J L Vildé; E Dournon; P Rajagopalan
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.